Log In Sign up
The largest database of trusted experimental protocols

V8879

Manufactured by Merck Group
Visit Supplier
Sourced in United States

The V8879 is a laboratory equipment product manufactured by Merck Group. It is designed for general laboratory use, but its core function is not provided in a detailed or unbiased manner.

Automatically generated - may contain errors

Lab products found in correlation

Doxorubicin, by Selleck Chemicals (1 mentions) Cisplatin, by Selleck Chemicals (1 mentions) Pembrolizumab, by Selleck Chemicals (1 mentions) Nivolumab, by Selleck Chemicals (1 mentions) Ipilimumab, by Selleck Chemicals (1 mentions) Vincristine, by Selleck Chemicals (1 mentions) S1208, by Selleck Chemicals (1 mentions) A2002, by Selleck Chemicals (1 mentions) A2001, by Selleck Chemicals (1 mentions) A2005, by Selleck Chemicals (1 mentions) D2650, by Merck Group (1 mentions) Quercetin q4951, by Merck Group (1 mentions) T7402, by Merck Group (1 mentions) Quercitrin q3001, by Merck Group (1 mentions) Fisetin f4043, by Merck Group (1 mentions) Synergy ht, by Agilent Technologies (1 mentions) Bk011p, by Cytoskeleton (1 mentions)

5 protocols using v8879

1

Organoid Chemotherapy and Immunotherapy Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Organoids were subsequently treated after 7 days of culture. Chemotherapies included cisplatin (1, 10, 100 µM) (232120, Sigma Aldrich), doxorubicin (0.1, 1, 10 µM) (S1208, Selleckchem), vincristine (0.1, 1, 10 µM) (V8879 Sigma Aldrich), doxorubicin with cisplatin (0.1/1, 1/10, 10/100 µM), cisplatin with etoposide (S1125, Selleckchem) (1/0.1, 10/1, 100/10 µM) (Selleckchem), and doxorubicin with vincristine (0.1/0.1, 1/1, 10/10 µM). For immunotherapy treatment, 100 nM of pembrolizumab (A2002, Selleckchem), ipilimumab (A2001, Selleckchem) or nivolumab (A2005, Selleckchem) was used on both iPTOs and PTOs in parallel treatments. Media was removed from the wells and drug solutions mixed in culture media were added. Organoids remained in treated media solution for 72 h prior to endpoint viability assessment.
Forsythe S.D., Erali R.A., Laney P., Sivakumar H., Li W., Skardal A., Soker S, & Votanopoulos K.I. (2022). Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research. Scientific Reports, 12, 13865.
+ Open protocol
+ Expand
2

Tubulin Polymerization Dynamics Assay

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
25μg of MAP-rich tubulin (Cytoskeleton, Inc.; #ML116) in general tubulin buffer (80mM PIPES, pH 6.9/ 2mM MgCl2/ 0.5mM EGTA/10μM fluorescence reporter) (Cytoskeleton, Inc.; #BP01) was combined with 1mM GTP, 15% tubulin glycerol cushion buffer (Cytoskeleton, Inc.; # BPST05-001) and the indicated concentrations of rigosertib (obtained from either Selleckchem [chemical grade] or Onconova Therapeutics, Inc. [pharmaceutical grade]), ON01500 (Reddy et al., 2011 (link)), and vincristine (Sigma-Aldrich; #V8879). All compounds were dissolved in DMSO and used as 25X stock solutions. The reactions were incubated at 37°C in a Synergy H1 Multi-mode Hybrid Reader (BioTek) and fluorescence measured every 30 s over the indicated period of time. Fluorescence values were normalized by subtracting the points obtained at the start of polymerization for each reaction from all subsequent data points.
Baker S.J., Cosenza S.C., Athuluri-Divakar S., Reddy M.V., Vasquez-Del Carpio R., Jain R., Aggarwal A.K, & Reddy E.P. (2020). A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent. Molecular cell, 79(1), 180-190.e4.
+ Open protocol
+ Expand
3

Evaluating Anticancer Effects of Phytochemicals

Check if the same lab product or an alternative is used in the 5 most similar protocols
Compounds evaluated were Ga (G7384), methyl gallate (274194), Myr (M6760), myricitrin (91255), quercetin (Q4951), quercitrin (Q3001), and fisetin (F4043) from Sigma-Aldrich© (St. Louis, MO, USA) (HPLC-grade). Control drugs were paclitaxel (5 µg/mL in cells; T7402, Sigma®), vincristine (20 µg/mL in cells; V8879, Sigma®, St. Louis, MO, USA), and carboplatin (50 mg/kg/3 alternating days/week in mice; C2538, Sigma®, St. Louis, MO, USA); all drugs are chemotherapeutic agents used in treatment against ovarian cancer. Vehicle controls were 1× PBS (100 µL/day in animals) or 0.5% DMSO-1X PBS (v/v in cells; D2650, Sigma®, St. Louis, MO, USA). Additional use of equipment and reagents are indicated in the text.
Varela-Rodríguez L., Sánchez-Ramírez B., Saenz-Pardo-Reyes E., Ordaz-Ortiz J.J., Castellanos-Mijangos R.D., Hernández-Ramírez V.I., Cerda-García-Rojas C.M., González-Horta C, & Talamás-Rohana P. (2021). Antineoplastic Activity of Rhus trilobata Nutt. (Anacardiaceae) against Ovarian Cancer and Identification of Active Metabolites in This Pathology. Plants, 10(10), 2074.
+ Open protocol
+ Expand
4

Vincristine Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cultures were treated by replacing half the media volume with either 0.02 µM or 1 µM vincristine (Sigma Aldrich v8879) diluted in culture media. In control conditions, half of the media volume was replaced with fresh media with <0.1% DMSO. After four hours of vincristine exposure, chambers were fixed, following the protocol described above, and analyzed.
Vaughan S.K., Sutherland N.M., Zhang S., Hatzipetros T., Vieira F, & Valdez G. (2018). The ALS-inducing factors, TDP43A315T and SOD1G93A, directly affect and sensitize sensory neurons to stress. Scientific Reports, 8, 16582.
+ Open protocol
+ Expand
5

Tubulin Polymerization Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Chemicals were tested in a commercially available cell-free biochemical assay (BK011P, Cytoskeleton, Inc). Briefly, control and experimental solutions were prepared and loaded in duplicate into a warm (37 °C) 96-well plate. A solution of purified tubulin and a fluorescent reporter were added to the wells containing the warm substances and placed into a prewarmed (37 °C) Biotek Synergy HT microplate reader where fluorescence was measured every minute for 60 min. Equimolar doses of paclitaxel (included in kit) and vincristine (V8879, Sigma-Aldrich) were included as positive and negative modulators of tubulin polymerization, respectively.
Pearson B.L., Simon J.M., McCoy E.S., Salazar G., Fragola G, & Zylka M.J. (2016). Identification of chemicals that mimic transcriptional changes associated with autism, brain aging and neurodegeneration. Nature Communications, 7, 11173.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!